Clinical evaluation demonstrates the effectiveness of immune checkpoint inhibitor re-challenge in advanced non-small cell lung cancer, suggesting a viable subsequent treatment strategy.
Our study shows the effectiveness of re-challenge of immune checkpoint inhibitors in a subset of non-small cell lung cancer patients. Re-challenge might become one of treatment option for advanced non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Niki et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: